Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634392 | 0.88 | MAPK13 (0.76) | NPC1RAB9ASMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL5634107 | 0.88 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL5634628 | 0.88 | MAPK13 (0.57) | NPC1RAB9ASMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL5395408 | 0.88 | MAPK13 (0.76) | NPC1RAB9ASMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL5635193 | 0.88 | MAPK13 (0.62) | NPC1RAB9ASMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL5634599 | 0.87 | MAPK13 (0.60) | NPC1RAB9ASMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL5395402 | 0.87 | MAPK13 (0.59) | NPC1RAB9ASMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL5634498 | 0.87 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL5635186 | 0.86 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2MAPK13MAPK12 | |
| SCHEMBL5635337 | 0.86 | MAPK13 (0.68) | NPC1RAB9ASMN1; SMN2MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253197-B2 | Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1539722-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-20040038990-A1 | Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004014884-A1 | THIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038990-A1 | Aminothiazole derivatives | FABP4, GPR119, ABAT | NPC1 572/4885RAB9A 1476/4885SMN1; SMN2 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.